Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.3%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYELGet Rating) were up 4.3% during mid-day trading on Wednesday . The stock traded as high as $3.18 and last traded at $3.17. Approximately 251,267 shares were traded during trading, a decline of 76% from the average daily volume of 1,031,935 shares. The stock had previously closed at $3.04.

Wall Street Analysts Forecast Growth

LYEL has been the subject of several research reports. HC Wainwright reduced their target price on Lyell Immunopharma from $12.00 to $11.00 in a report on Wednesday, November 9th. The Goldman Sachs Group downgraded Lyell Immunopharma from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $13.00 to $7.00 in a report on Friday, November 11th. Finally, Morgan Stanley cut their target price on shares of Lyell Immunopharma from $7.00 to $4.00 and set an “equal weight” rating on the stock in a report on Tuesday.

Lyell Immunopharma Trading Up 4.3 %

The company has a 50 day simple moving average of $3.53 and a 200 day simple moving average of $5.51. The stock has a market capitalization of $790.36 million, a PE ratio of -3.53 and a beta of -1.92.

Lyell Immunopharma (NASDAQ:LYELGet Rating) last issued its quarterly earnings results on Tuesday, November 8th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. Lyell Immunopharma had a negative return on equity of 29.54% and a negative net margin of 660.62%. On average, equities research analysts predict that Lyell Immunopharma, Inc. will post -1 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in Lyell Immunopharma in the second quarter worth $316,000. Amalgamated Bank acquired a new position in shares of Lyell Immunopharma during the 1st quarter worth $111,000. Camden Capital LLC purchased a new position in shares of Lyell Immunopharma in the 3rd quarter valued at about $110,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Lyell Immunopharma in the third quarter valued at about $114,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Lyell Immunopharma during the third quarter worth about $749,000. 45.04% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.

Further Reading

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with's FREE daily email newsletter.